Eyenovia to Consider 'Strategic Options' After Phase 3 Study Fails to Meet Primary Endpoint

MT Newswires Live11-15 20:54

Eyenovia (EYEN) said Friday that a phase 3 study evaluating its drug-device combination of low-dose atropine in the company's Optejet dispensing platform for pediatric progressive myopia, did not meet its primary endpoint.

The independent Data Review Committee found no significant difference in myopia progression between the treatment arms of 0.01% and 0.1% atropine and the placebo.

Eyenovia said it would terminate the study despite safety data indicating that all dosages and placebo were well-tolerated.

Eyenovia said it is also considering different strategic options, including a business combination, reverse merger, asset sales, or a combination of these options.

Eyenovia shares were down more than 50% in recent premarket trading.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2483762553?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-15 20:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2483762553","market":"nz","top_or_hot":-1,"title":"Eyenovia to Consider 'Strategic Options' After Phase 3 Study Fails to Meet Primary Endpoint","media":"MT Newswires Live","content":"<html><body><p> Eyenovia (EYEN) said Friday that a phase 3 study evaluating its drug-device combination of low-dose atropine in the company's Optejet dispensing platform for pediatric progressive myopia, did not meet its primary endpoint.</p><p>The independent Data Review Committee found no significant difference in myopia progression between the treatment arms of 0.01% and 0.1% atropine and the placebo.</p><p>Eyenovia said it would terminate the study despite safety data indicating that all dosages and placebo were well-tolerated.</p><p>Eyenovia said it is also considering different strategic options, including a business combination, reverse merger, asset sales, or a combination of these options.</p><p>Eyenovia shares were down more than 50% in recent premarket trading.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Eyenovia to Consider 'Strategic Options' After Phase 3 Study Fails to Meet Primary Endpoint</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEyenovia to Consider 'Strategic Options' After Phase 3 Study Fails to Meet Primary Endpoint\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-15 20:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Eyenovia (EYEN) said Friday that a phase 3 study evaluating its drug-device combination of low-dose atropine in the company's Optejet dispensing platform for pediatric progressive myopia, did not meet...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EYEN","symbol_name":"Eyenovia Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2483762553","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2483762553","pubTimestamp":1731675280,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Eyenovia  said Friday that a phase 3 study evaluating its drug-device combination of low-dose atropine in the company's Optejet dispensing platform for pediatric progressive myopia, did not meet its primary endpoint.The independent Data Review Committee found no significant difference in myopia progression between the treatment arms of 0.01% and 0.1% atropine and the placebo.Eyenovia said it would terminate the study despite safety data indicating that all dosages and placebo were well-tolerated.Eyenovia said it is also considering different strategic options, including a business combination, reverse merger, asset sales, or a combination of these options.Eyenovia shares were down more than 50% in recent premarket trading.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"EYEN":"Eyenovia Inc.","BK4007":"制药"},"translate_title":"3期研究未能达到主要终点后，Eyenovia将考虑“战略选择”","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EYEN":0.9},"content_text":"Eyenovia (EYEN) said Friday that a phase 3 study evaluating its drug-device combination of low-dose atropine in the company's Optejet dispensing platform for pediatric progressive myopia, did not meet its primary endpoint.The independent Data Review Committee found no significant difference in myopia progression between the treatment arms of 0.01% and 0.1% atropine and the placebo.Eyenovia said it would terminate the study despite safety data indicating that all dosages and placebo were well-tolerated.Eyenovia said it is also considering different strategic options, including a business combination, reverse merger, asset sales, or a combination of these options.Eyenovia shares were down more than 50% in recent premarket trading.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2483762553"}